Treatment of acute promyelocytic leukemia with arsenic compounds: In vitro and in vivo studies

Seminars in Hematology

Volumn 38, Issue 1, 2001, Pages 26-36

  Zhu, Chen ^a   Guo Qiang, Chen ^a   Zhi Xiang, Shen ^a   Sai Juan, Chen ^a   Zhen Yi, Wang ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC DERIVATIVE; ARSENIC SULFIDE; ARSENIC TRIOXIDE; HISTONE; RETINOIC ACID; UNCLASSIFIED DRUG;

ACETYLATION; ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CELL DIFFERENTIATION; DISEASE SEVERITY; DOSE RESPONSE; ELECTROCARDIOGRAM; GASTROINTESTINAL SYMPTOM; GENE ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; LIVER DYSFUNCTION; LIVER INJURY; MEMBRANE POTENTIAL; MITOCHONDRION; NEUROPATHY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN MANIFESTATION;

EID: 0035143574     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(01)90003-4     Document Type: Article

References (37)

1. The impact of all-trans retinoic acid on the coagulopathy of acute promyelocytic leukemia
2. RAR-independent RXR signaling induced t(15;17) leukemia cell maturation
3. Cure of leukemia
4. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia
5. Leucocytosis and the "retinoic acid syndrome" during induction treatment of acute promyelocytic leukemia with arsenic trioxide
6. 3 exerts dose-dependent dual effect on APL cells in vitro and in vivo
7. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins
8. Retinoic acid regulatory pathways, chromosomal translocations and acute promyelocytic leukemia
9. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic through modulation of the glutathion
10. Dithiothreitol enhances arsenic trioxide-induced apoptosis in NB4 cells
11. Effect of aggressive daunorubicin therapy on survival in acute promyelocytic leukemia
12. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway
13. Use of all-trans retinoic acid in treatment of acute promyelocytic leukemia
14. Clinical study on the treatment of acute promyelocytic leukemia mainly with composite indigo naturalis tablets
15. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukemia
16. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia
17. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore
18. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells
19. 4). A mono-institutional study
20. Leucémie aiguë promyélocytaire: Étude rétrospective de 119 malades traités par daunorubicine
21. Caspases find a new place to hide
22. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
23. Conjugating with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus
24. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide. Remission induction, follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed APL patients
25. The epidemiology of human arsenic exposure
26. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells
27. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients
28. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
29. Multiple centers trial of arsenic trioxide (AT) in acute promyelocytic leukemia (APL)
30. PIC-1/ SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia
31. Treatment of acute promyelocytic leukemia by Al-1 therapy
32. PML is essential for multiple apoptotic pathways
33. Arsenic trioxide-treated 72 cases of acute promyelocytic leukemia
34. Establishment of a human acute promyelocytic leukemia-ascitis model in SCID mice
35. Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents
36. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of APL
37. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations